Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Sareum Hldgs Plc

Healthcare GB SAR

23.25GBX
-0.25(1.06%)

Last update at 2026-06-05T15:25:00Z

Day Range

23.0024.00
LowHigh

52 Week Range

9.5029.00
LowHigh

Fundamentals

  • Previous Close 23.50
  • Market Cap22.09M
  • Volume220250
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.38100M
  • Revenue TTM0.05M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.05M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -4.90300M -4.54200M -4.02500M -2.57900M -1.71788M
Minority interest - - - - -
Net income -4.43800M -3.42000M -3.19200M -2.17200M -1.50038M
Selling general administrative 3.38M 4.60M 4.05M 2.58M 1.88M
Selling and marketing expenses - 3.56M - - -
Gross profit - -0.00100M - - -
Reconciled depreciation 0.00000M 0.00100M 0.00100M 0.00200M 0.00109M
Ebit - -4.54200M -4.04800M -2.58000M -1.71797M
Ebitda -3.38200M -4.54100M - -2.57500M -1.70293M
Depreciation and amortization - 0.00100M - 0.00500M 0.02M
Non operating income net other - - - - -
Operating income -3.38000M -4.63300M -4.04800M -2.58000M -1.71797M
Other operating expenses 3.38M 4.63M - 2.58M 1.70M
Interest expense 1.60M 0.00000M - 0.00100M 0.01M
Tax provision -0.46500M -1.18200M -0.83300M -0.40700M -0.21750M
Interest income 0.08M 0.03M 0.04M 0.00100M 0.00009M
Net interest income 0.08M 0.03M 0.04M 0.00100M 0.00009M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.46500M -1.18200M -0.83300M -0.40700M -0.21750M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 3.38M 4.63M 4.05M 2.58M 1.70M
Cost of revenue - 0.00100M - - -
Total other income expense net -1.52300M 0.03M - 0.00100M 0.00009M
Discontinued operations - - - - -
Net income from continuing ops -4.43800M -3.42000M -3.19200M -2.17200M -1.50038M
Net income applicable to common shares - - -3.19200M -2.17200M -1.50038M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 4.23M 2.77M 2.02M 4.79M 3.08M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 1.22M 0.50M 0.50M 0.37M
Total liab 1.95M 0.65M 0.87M 0.46M 0.28M
Total stockholder equity 2.28M 2.11M 1.15M 4.33M 2.80M
Deferred long term liab - - - - -
Other current liab 1.73M 0.09M 0.17M 0.07M 0.18M
Common stock 1.68M 1.35M 0.85M 0.85M 0.83M
Capital stock 1.68M 1.35M 0.85M 0.85M 0.83M
Retained earnings -28.78600M -24.36900M -20.96200M -17.77000M -15.63500M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 3.55M 1.46M 0.99M 4.26M 2.69M
Cash and equivalents - - - - -
Total current liabilities 1.95M 0.65M 0.87M 0.46M 0.28M
Current deferred revenue - - - - -
Net debt -3.54600M -1.45900M -0.99400M -4.26100M -2.68616M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 29.02M 24.80M 21.26M 21.25M 17.60M
Property plant equipment - - 0.00100M 0.00200M 0.00154M
Total current assets 4.23M 2.76M 1.97M 4.76M 3.05M
Long term investments - - - - -
Net tangible assets - - 1.15M 4.33M 2.80M
Short term investments - - - - 2.69M
Net receivables 0.68M 0.08M 0.90M 0.46M 0.32M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.20M 0.54M 0.69M 0.39M 0.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.36M 0.33M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00900M 0.05M 0.02M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00900M 0.05M 0.03M 0.03M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.09M 0.00900M -0.04100M -0.00200M -0.03795M
Change to liabilities - - 0.41M 0.17M 0.09M
Total cashflows from investing activities 0.09M 0.00900M - -0.00200M -0.03786M
Net borrowings - - - - -
Total cash from financing activities 4.55M 4.38M 3.71M 3.71M 2.49M
Change to operating activities - - - 0.23M 0.23M
Net income -4.90300M -3.42000M -4.02400M -2.58000M -1.71788M
Change in cash 2.09M 0.47M -3.26700M 1.57M 0.88M
Begin period cash flow 1.46M 0.99M 4.26M 2.69M 1.80M
End period cash flow 3.55M 1.46M 0.99M 4.26M 2.69M
Total cash from operating activities -2.55100M -3.91900M -3.26700M -2.13100M -1.57066M
Issuance of capital stock 4.70M 4.38M 0.00000M 3.71M 2.49M
Depreciation 0.00000M 0.00100M 0.00100M 0.00200M 0.00109M
Other cashflows from investing activities 0.08M 0.03M 0.04M 0.00100M 0.00009M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.10400M 0.04M -0.06500M 0.06M -0.08755M
Sale purchase of stock - - - - 2.49M
Other cashflows from financing activities -0.15200M -0.02300M -0.04100M -0.00200M -0.03786M
Change to netincome - - -0.42200M -0.18800M -0.06943M
Capital expenditures 0.00000M 3.89M 0.00300M 0.00300M 0.00326M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.40400M -0.17100M 0.35M 0.23M -0.00193M
Stock based compensation 1.60M 0.00000M - - -
Other non cash items 1.16M -0.32900M 0.41M 0.22M 0.15M
Free cash flow -2.55100M -3.91900M -3.26700M -2.13400M -1.57066M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SAR
Sareum Hldgs Plc		 -0.25 1.06% 23.25 - 95.24 4506.84 17.92 4749.70 -17.1315
GNS
Genus PLC		 - -% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -9.7 6.93% 130.30 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 30.00 5.00% 630.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 1.50 2.14% 71.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company has strategic collaboration with Receptor.AI launched in August 2025 to accelerate discovery and optimisation of BBB-permeable TYK2/JAK1 inhibitors; and completion of initial stage expected Q4 2025. Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.

Sareum Hldgs Plc

Langford Arch, Cambridge, United Kingdom, CB22 3FX

Key Executives

Name Title Year Born
Dr. Tim J. Mitchell Ph.D. Founder, CEO & Exec. Director 1960
Dr. John C. Reader Ph.D. Founder, Chief Scientific Officer & Exec. Director 1967
Mr. Anthony Bunn F.C.M.A., FCMA Sec. NA
Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D. Executive Chairman 1958
Dr. John Charles Reader Ph.D. Founder, Chief Scientific Officer & Executive Director 1967
Dr. Timothy John Mitchell Ph.D. Founder, COO & Executive Director 1960
Mr. Clive H. W. Birch F.C.A. Secretary & Senior Independent Non-Executive Director 1953
Alexandra Harrison Head of IR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions